7730 Federal Register / Vol. 86, No. 19 / Monday, February 1, 2021 / Notices 

such as when the COVID vaccine is 

accessible to residents, facility staff, and 

individuals working for the LTCO 

program; 

iii. Conducting education and 

outreach on abuse and neglect 

identification and prevention during the 

COVID public health emergency to 

residents, their families and facility 

staff; 

iv. Enabling travel for representatives 

of the LTCO Office to ensure all 

residents have access to an LTCO; 

v. Purchase of needed Personal 

Protective Equipment; 

vi. Purchase of technology; and 

vii. Enabling participation in statelevel ‘‘strike teams’’ to address 

complaints related to care and neglect. 

b. Assurance that these funds will 

supplement, and not supplant, existing 

funding for the State LTCO program; 

and 

c. Assurance that State Agencies on 

Aging will timely submit to ACL semiannual federal financial reports and 

annual program reports related to the 

activities performed. 

4. DUNS Number 

All grant applicants must obtain and 

keep current a D–U–N–S number from 

Dun and Bradstreet. It is a nine-digit 

identification number, which provides 

unique identifiers of single business 

entities. The D–U–N–S number can be 

obtained from: https://iupdate.dnb.com/ 

iUpdate/viewiUpdateHome.htm. 

5. Intergovernmental Review 

Executive Order 12372, 

Intergovernmental Review of Federal 

Programs, is not applicable to these 

grant applications. 

IV. Submission Information 

1. Letters of Assurance should be 

addressed to: Alison Barkoff, Acting 

Administrator and Assistant Secretary 

for Aging, Administration for 

Community Living, 330 C Street SW, 

Washington, DC 20201. 

Letters of Assurance should be 

submitted electronically via email to the 

ACL Regional Administrator for each 

state listed in the Agency Contacts 

below. 

2. Submission Dates and Times: 

To receive consideration, Letters of 

Assurance must be submitted by 11:59 

p.m. Eastern Time on March 3, 2021. 

Letters of Assurance should be 

submitted electronically via email and 

have an electronic time stamp 

indicating the date/time submitted. 

VII. Agency Contacts 

Direct inquiries regarding 

programmatic issues to Regional 

Administrators: 

Covered states ACL regional administrator 

Region I .................. CT, MA, ME, NH, RI, VT ....................... Jennifer Throwe, Email: jennifer.throwe@acl.hhs.gov, Phone: 617–565–1158. 

Region II ................. NY, NJ, PR, VI ...................................... Kathleen Otte, Email: kathleen.otte@acl.hhs.gov, Phone: 212–264–2976. 

Region III ................ DC, DE, MD, PA, VA, WV ..................... Rhonda Schwartz, Email: rhonda.schwartz@acl.hhs.gov, Phone: 267–831– 

2329. 

Region IV ................ AL, FL, GA, KY, MS, NC, SC, TN ........ Costas Miskis, Email: Constantinos.Miskis@acl.hhs.gov, Phone: 404–562– 

7600. 

Region V ................. IL, IN, MI, MN, OH, WI .......................... Amy Wiatr-Rodriguez, Email: Amy.Wiatr-Rodriguez@acl.hhs.gov, Phone: 312– 

938–9858. 

Region VI ................ AR, LA, OK, NM, TX ............................. Derek Lee, Email: derek.lee@acl.hhs.gov, Phone: 214–767–1865. 

Region VII ............... IA, KS, MO, NE ..................................... Lacey Boven, Email: lacey.boven@acl.hhs.gov, Phone: 816–702–4180. 

Region VIII .............. CO, MT, UT, WY, ND, SD .................... Percy Devine, Email: percy.devine@acl.hhs.gov, Phone: 303–844–2951. 

Region IX ................ CA, NV, AZ, HI, GU, CNMI, AS ............ Fay Gordon, Email: Fay.Gordon@acl.hhs.gov, Phone: 415–437–8780. 

Region X ................. AK, ID, OR, WA ..................................... Louise Ryan, Email: Louise.Ryan@acl.hhs.gov, Phone: (206) 615–2299. 

Dated: January 27, 2021. 

Alison Barkoff, 

Acting Administrator and Assistant Secretary 

for Aging. 

[FR Doc. 2021–02092 Filed 1–29–21; 8:45 am] 

BILLING CODE 4154–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Tenth Meeting of the National Clinical 

Care Commission 

AGENCY: Office on Women’s Health, 

Office of the Assistant Secretary for 

Health, Office of the Secretary, 

Department of Health and Human 

Services. 

ACTION: Notice. 

SUMMARY: The National Clinical Care 

Commission (the Commission) will 

conduct its tenth meeting virtually on 

February 17, 2021. The Commission is 

charged to evaluate and make 

recommendations to the U.S. 

Department of Health and Human 

Services (HHS) Secretary and Congress 

regarding improvements to the 

coordination and leveraging of federal 

programs related to diabetes and its 

complications. 

DATES: The meeting will take place on 

February 17, 2021, from 1 p.m. to 

approximately 5:30 p.m. Eastern 

Standard time (EST). 

ADDRESSES: The meeting will be held 

online via webinar. To register to attend 

the meeting, please visit the registration 

website at: https://

kauffmaninc.adobeconnect.com/nccc_

feb_2021/event/event_info.html. 

FOR FURTHER INFORMATION CONTACT: 

Clydette Powell, M.D., MPH, FAAP, 

Acting Designated Federal Officer, 

National Clinical Care Commission, 

U.S. Department of Health and 

Human Services Office on Women’s 

Health, 200 Independence Ave. SW, 

7th Floor, Washington, DC 20201, 

Phone: (240) 453–8239, Email: OHQ@

hhs.gov. 

SUPPLEMENTARY INFORMATION: The 

National Clinical Care Commission Act 

(Pub. L. 115–80) requires the HHS 

Secretary to establish the National 

Clinical Care Commission. The 

Commission consists of representatives 

of specific federal agencies and nonfederal individuals who represent 

diverse disciplines and views. The 

Commission will evaluate and make 

recommendations to the HHS Secretary 

and Congress regarding improvements 

to the coordination and leveraging of 

federal programs related to diabetes and 

its complications. 

The tenth meeting will be held 

virtually, will consist of updates from 

the Commission’s three subcommittees, 

and include another round of potential 

‘‘action plans,’’ or recommendations, 

from each subcommittee. The final 

meeting agenda will be available prior 

to the meeting at: https://health.gov/ourwork/health-care-quality/nationalclinical-care-commission/meetings. 

Public Participation at Meeting: The 

Commission invites public comment on 

Federal Register / Vol. 86, No. 19 / Monday, February 1, 2021 / Notices 7731 

issues related to the Commission’s 

charge. There will be an opportunity for 

limited oral comments (each no more 

than 3 minutes in length) at this virtual 

meeting. Virtual attendees who plan to 

provide oral comments at the 

Commission meeting during a 

designated time must register prior to 

the meeting at: https://

kauffmaninc.adobeconnect.com/nccc_

feb_2021/event/event_info.html. 

Written comments are welcome 

throughout the entire development 

process of the Commission’s work and 

may be emailed to OHQ@hhs.gov. 

Written comments should not exceed 

three pages in length. 

Individuals who need special 

assistance, such as sign language 

interpretation or other reasonable 

accommodations, should indicate the 

special accommodation when 

registering online or by notifying 

Jennifer Gillissen at jennifer.gillissen@

kauffmaninc.com by February 8, 2021. 

Authority: The National Clinical Care 

Commission is authorized by the 

National Clinical Care Commission Act 

(Pub. L. 115–80). The Commission is 

governed by provisions of the Federal 

Advisory Committee Act (FACA), Public 

Law 92–463, as amended (5 U.S.C., 

App.) which sets forth standards for the 

formation and use of federal advisory 

committees. 

Dated: January 25, 2021. 

Dorothy A. Fink, 

Deputy Assistant Secretary for Women’s 

Health, Office of the Assistant Secretary for 

Health. 

[FR Doc. 2021–02037 Filed 1–29–21; 8:45 am] 

BILLING CODE 4150–32–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Extension of Designation of Scarce 

Materials or Threatened Materials 

Subject to COVID–19 Hoarding 

Prevention Measures; Extension of 

Effective Date With Modifications 

AGENCY: Department of Health and 

Human Services (HHS). 

ACTION: Notice. 

SUMMARY: The Department of Health and 

Human Services (HHS) provides notice 

of the extension of the designation 

issued on July 30, 2020 designating 

health and medical resources necessary 

to respond to the spread of the virus 

associated with Coronavirus Disease 

2019 (COVID–19) that are scarce or the 

supply of which would be threatened by 

excessive accumulation by people or 

entities not needing the excess supplies. 

This notice extends the designation and 

updates the list of scarce or threatened 

materials to include certain classes and 

sizes of hypodermic needles and 

syringes. 

DATES: This action took effect February 

1, 2021 and terminates on June 30, 2021. 

FOR FURTHER INFORMATION CONTACT: 

Paige Ezernack: 202–260–0365; 

PaigeEzernack@hhs.gov. 

SUPPLEMENTARY INFORMATION: On March 

23, 2020, and in response to the spread 

of the virus associated with COVID–19, 

President Trump signed Executive 

Order 13910 (Executive Order) to 

prevent hoarding of health and medical 

resources necessary to respond to the 

spread of COVID–19 within the United 

States. As provided in the Executive 

Order, it is the policy of the United 

States that health and medical resources 

needed to respond to the spread of 

COVID–19, such as personal protective 

equipment and sanitizing and 

disinfecting products, are appropriately 

distributed. This policy furthers the goal 

of protecting the Nation’s healthcare 

systems from undue strain. 

Through the Executive Order, the 

President delegated, to the Secretary of 

Health and Human Services (the 

Secretary), his authority under section 

102 of the Defense Production Act of 

1950, 50 U.S.C. 4512, as amended (the 

Act), to prevent hoarding of health and 

medical resources necessary to respond 

to the spread of COVID–19 within the 

United States, and his authority to 

implement the Act in subsection III of 

chapter 55 of title 50, United States 

Code (50 U.S.C. 4554, 4555, 4556, and 

4560). Under this delegation and the 

Act, the Secretary may designate such 

resources as scarce materials or 

materials the supply of which would be 

threatened by such accumulation 

(threatened materials). The Secretary 

may also prescribe conditions with 

respect to accumulation of such 

materials in excess of the reasonable 

demands of business, personal, or home 

consumption. The Act prohibits any 

person or entity from accumulating 

designated materials (1) in excess of the 

reasonable demands of business, 

personal, or home consumption, or (2) 

for the purpose of resale at prices in 

excess of prevailing market prices. 

The March 25 Designation Notice 

issued by HHS designates scarce 

materials or threatened materials that 

are subject to the hoarding prevention 

measures authorized under the 

Executive Order and the Act. See 85 FR 

17592. (Mar. 30, 2020). Under 50 U.S.C. 

4552(13), the term ‘‘materials’’ includes: 

‘‘(A) any raw materials (including 

minerals, metals, and advanced 

processed materials), commodities, 

articles, components (including critical 

components), products, and items of 

supply; and (B) any technical 

information or services ancillary to the 

use of any such materials, commodities, 

articles, components, products, or 

items.’’ For purposes of the March 25 

Designation Notice, the term ‘‘scarce 

materials or threatened materials’’ 

means health or medical resources, or 

any of their essential components, 

determined by the Secretary to be 

needed to respond to the spread of 

COVID–19 and which are, or are likely 

to be, in short supply or the supply of 

which would be threatened by hoarding. 

85 FR at 17592. Designated scarce 

materials or threatened materials are 

subject to periodic review by the 

Secretary. 

The designation is not a ‘‘regulation’’ 

under the Administrative Procedure Act 

(APA). See 50 U.S.C. 4559 (providing an 

exemption from the APA). To the extent 

that it is, the Secretary finds that, in 

light of the current pandemic, urgent 

and compelling circumstances make 

compliance with public comment 

requirements impracticable. See Id. 

The March 25 Designation Notice was 

scheduled to terminate 120 days from 

the date of publication, unless 

superseded by a subsequent notice. 

Given the ongoing pandemic, the 

Secretary finds good cause to extend the 

March 25 Designation Notice, as 

modified by the June 30, 2020 and July 

30, 2020 notices, through June 30, 2021. 

The Secretary also finds good cause to 

include the following modifications and 

additions to the list of scarce or 

threatened materials: 

1. In FR Doc. 2020–06641 of March 

30, 2020 (85 FR 17592), add the 

following text: 

(i) On page 17593, first column, (7) 

Sterilization services, add ‘‘or are 

authorized by FDA under section 564 of 

the FD&C Act for purposes of 

decontamination’’ 

(ii) On page 17593, first column, (11) 

Face masks, remove ‘‘PPE’’ 

(iii) On page 17593, first column, (12) 

Surgical masks, remove ‘‘PPE’’ 

2. Add ‘‘Syringes and hypodermic 

needles (whether distributed separately 

or attached together) generally used in 

the United States for vaccinations that 

are either: 

(i) Piston syringes in 1 ml or 3 ml 

sizes that allow for the controlled and 

precise flow of liquid as described by 21 

CFR 880.5860, that are compliant with 

ISO 7886–1:2017 and use only Current 

Good Manufacturing Practices (CGMP) 

processes; or 

(ii) Hypodermic single lumen needles 

between 1′′; and 1.5′′ and 22 to 25 gauge 

between 1′′ and 1.5′′ and 22 to 25 gauge